Skip to content

Advertisement

  • Research note
  • Open Access

Profile of the 2016 dengue outbreak in Nepal

  • 1,
  • 2,
  • 1,
  • 3,
  • 4,
  • 5 and
  • 3, 5Email authorView ORCID ID profile
Contributed equally
BMC Research Notes201811:423

https://doi.org/10.1186/s13104-018-3514-3

Received: 13 May 2018

Accepted: 18 June 2018

Published: 3 July 2018

Abstract

Objective

The objective of this study was to obtain clinical, virological and demographic data detailing the 2016 dengue outbreak in Nepal.

Results

Dengue disease was first reported in Nepal in 2004 and several major outbreaks have occurred since then, with a significant impact on public health. An outbreak of dengue fever occurred in Nepal during June to November 2016, with a peak number of cases reported in September. 1473 patients with laboratory confirmed DENV infections visited or were admitted to hospitals during this period. The most common clinical symptoms included fever, headache, joint pain and thrombocytopenia. Serotyping of 75 serum samples from patients having fever for less than 4 days was carried out with a dengue virus (DENV) serotype-specific RT-PCR strategy. Our results indicate that the dengue outbreak in Nepal during 2016 was caused predominantly, if not exclusively, by DENV-1, representing a shift in the prevailing serotype from DENV-2, the dominant serotype characterizing the 2013 dengue epidemic in Nepal. Hopefully, this report will assist Nepalese public health agencies in developing improved dengue-related programs including mosquito-vector control, DENV surveillance, and diagnosis and treatment of dengue fever patients, in order to reduce the impact of future dengue epidemics.

Keywords

  • Dengue fever
  • Dengue virus serotype 1
  • Outbreak
  • Nepal

Introduction

Dengue virus (DENV) is a species in the genus Flavivirus of the family Flaviviridae and exists as numerous genetically distinct strains, each of which can be categorized into one of the four serotypes: DENV-1, DENV-2, DENV-3, and DENV-4 [1]. DENV is a single stranded, positive sense RNA virus, approximately 11 kb long. The genome codes for three structural proteins-nucleocapsid or core (C), a membrane-associated (M), an enveloped (E) glycoprotein, and seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). DENV is transmitted to humans primarily by Aedes aegypti mosquitos and is the causative agent of dengue disease [2].

DENV occurs in tropical and subtropical regions worldwide and is the most common and widespread arboviral infection of humans. DENV infections typically result in tens of millions of clinical cases of dengue disease yearly, causing an enormous health, social and economic burden, mostly in low- and middle-income countries [3] Until recently, dengue disease was generally classified as dengue fever (DF), dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). However, in 2009, The World Health Organization (WHO) [4] revised the guidelines for dengue disease classification. Cases of clinical infection are now classified as mild, moderate or severe dengue disease [5]. Mild or moderate dengue disease are considered non-life-threatening whereas severe dengue disease (associated with severe plasma leakage, severe bleeding, or organ failure) is considered a life-threatening condition (previously referred to as DHF and/or DSS). For the purposes of our study, we refer to mild or moderate dengue disease cases together as dengue fever (DF) to distinguish them from cases of severe dengue disease (SDD) [6]. Any symptomatic case of dengue disease is a miserable experience and results in several days or more of convalescence. It is generally accepted that a symptomatic initial DENV infection, with any single serotype, typically presents as mild or moderate dengue disease, but that subsequent infection with a DENV strain belonging to a different serotype is more likely to result in severe dengue disease, which can be fatal. The immunopathologic phenomenon in which non-neutralizing antibodies produced in response to an initial infection with one serotype remain in circulation and contribute to a more severe clinical outcome upon infection with a second serotype is known as antibody dependent enhancement (ADE) [7].

Nepal is a Himalayan country surrounded by the dengue-endemic countries India and China [8, 9]. In Nepal, the first case of dengue disease was reported in 2004 [10] followed by 32 laboratory confirmed cases during 2006. Virus sequencing of patient serum samples obtained during the 2006 outbreak showed that DENV strains from all four serotypes were circulating in the nine Terai regions of southern Nepal, however, no detailed epidemiologic data was collected [10, 11]. A small number of dengue disease cases were reported in 2007–2009 [10] followed by major outbreaks in 2010 and 2013 with the prevailing serotypes DENV-1 and DENV-2 respectively [12]. Another major dengue outbreak occurred in 2016, with clinical cases reported from several districts of Nepal. The aim of our study was investigate the characteristics and extent of the 2016 outbreak, including DENV serotype identification and demographic data associated with clinical cases.

Main text

Methods

Clinical information and blood samples were collected from patients who visited or were admitted to various clinics or hospitals during June–November 2016. Disease symptoms were diagnosed by clinicians and classified as dengue fever (DF) or severe dengue disease (SDD) based on the WHO classification (WHO 2009) [13]. Patients were suspected to have DF when presenting with acute onset of high fever lasting for 2–7 days and exhibiting at least two of the following symptoms: fever, rash, headache, retro-orbital pain and leucopenia. A patient was suspected of having SDD when hemorrhagic manifestations such as mucosal bleeding and plasma leakage were observed in addition to the features of DF described above. Patients suspected of having DF or SDD underwent further examinations for confirmation of the illness. A case was labeled as “probable” if the patient was found to harbor IgM antibodies specific against DENV or as “confirmed” when the presence DENV RNA was detected by RT-PCR.

Blood draws were collected from patients at the various clinical settings. Serum samples were obtained by centrifugation, and then assayed with the Panbio Dengue IgM capture ELISA diagnosis kit, for the detection of IgM antibodies against DENV, following protocols supplied with the product by the manufacturer. For detection of dengue NS1 antigen in the acute sera, the NS1 ELISA kit (Pan Bio, Australia) and its supplied protocols were used. For each sample, Panbio units were calculated according to the manufacturer’s instructions to determine if positive or negative for DENV.

Dengue viral RNA was assayed by reverse transcriptase PCR (RT-PCR) using primers designed to amplify a specific region of the Core-Pre-membrane (C-PrM) region of DENV genomic RNA. Briefly, RNA was isolated from 140 μl of each serum sample using the Nucleospin viral RNA isolation kit (MACHEREY–NAGEL, Germany) according to the manufacturer’s instructions. RT-PCR was then carried out using Access quick RT PCR Master mix (Promega, USA) with primers D1F and Dencom R2, for 40 cycles, as described previously (Additional file 1: Table S1) [14]. These primers target sequences which are highly conserved across the DENV virome and amplify a 654 bp product (corresponding to the sequence between nt 134–785) [14, 15]. A nested-primers PCR strategy was then used to distinguish the serotype identity of the amplicons. This method utilized a single forward primer (D1F) and series of reverse primers DNS1, DNS2, DNS3, and DNS4, which specifically distinguish DENV-1, DENV-2, DENV-3 and DENV-4 respectively (Additional file 1: Table S1) [16].

Results

The first significant outbreak of dengue in Nepal was reported in 2006 when around 35 cases occurred. In the years 2007–2009, 10–30 confirmed cases were reported each year. Major outbreaks occurred in 2010 and 2013 with 917 and 683 cases reported, respectively, while the intervening years of 2011–2012 had 79 and 183 cases respectively [17]. In 2016, 5769 persons with symptoms consistent with dengue disease visited various hospitals and clinics in Nepal. Among those, 1473 were dengue-positive based on laboratory confirmation representing a marked increase compared to previous years. Serotyping of 75 serum samples from patients having fever for < 4 days was carried out with a DENV (dengue virus)-serotype-specific reverse transcriptase polymerase chain (RT-PCR) strategy. The highest number of cases was in Chitwan district followed by other southern Nepal districts Jhapa, Rupandehi and Makwanpur; however clinical dengue cases were reported over a wide geographic area, in 32 of Nepal’s 75 total districts (Fig. 1). The major clinical features of patients who reported to the various clinical settings during this outbreak were fever (100%), headache (71.3%), rashes (11.3%), retro-orbital pain (23.5%), vomiting (23.4%), joint pain (32.1%) and thrombocytopenia (85.7%). Minor symptoms reported included abdominal pain and a feeling of restlessness. The infection was found to be at a higher in males in the 19–41 years age group with a child–adult ratio of 0.3:1 and male–female ratio of 6:4. The patients had a mean age (± standard deviation) of 37.85 (± 7.14) years. Clinical symptoms and serotype analysis of ten dengue disease patients with platelet counts of less than 50,000/mm3 are shown in Table 1. The outbreak peaked in September, corresponding to the tail end of monsoon season in Nepal, and subsided around the last week of November (Fig. 2).
Figure 1
Fig. 1

Incidence of dengue disease cases in Nepalese districts during 2016 outbreak

Table 1

Symptoms and serotype of ten dengue disease patients with platelet count of less than 50,000/mm3

ID

Age (years)

Sex

Disease category

platelet count (× 1000/mm3)

Serotype

NS1 ELISA

Symptoms

1

22

M

DF

45

DENV-1

+

Fever, headache, joint pain

2

37

F

DF

40

DENV-1

+

Fever, headache, joint pain

3

33

M

DF

39

DENV-1

+

Fever, restlessness, vomiting

4

50

M

DF

32

DENV-1

+

Fever, headache, vomiting, joint-pain, restlessness

5

45

M

DF

45

DENV-1

+

Fever, headache restlessness, loss of appetite

6

24

M

DF

42

DENV-1

+

Fever, joint pain, loss of appetite

7

18

F

DF

30

DENV-1

+

Fever, restlessness, loss of appetite

8

36

M

DF

29

DENV-1

+

Fever, headache, nausea

9

28

M

DF

37

DENV-1

+

Fever, anorexia, nausea, fever, abdominal pain

10

52

F

DF

47

DENV-1

+

Fever, headache, muscular pain, nausea

Figure 2
Fig. 2

Monthly distribution of dengue disease cases during 2016 outbreak

Discussion

Since the first reported endogenous cases in 2006, the number of dengue disease cases annually has been increasing overall in Nepal [18]. The geographical footprint of both the Ae. aegypti vector and dengue disease has expanded from the Terai lowland of southern Nepal and now includes the most populous urban area, Kathmandu, located in a highland region of central Nepal [19]. As observed in previous outbreaks as well, there was a sharp increase in both the number of mosquitos and number of dengue disease cases during and soon after the monsoon season of June–September in 2016. In this study, the majority of infected patients were of age 19–41 years, with a higher number of male than females represented, a pattern similar to that reported for previous outbreaks [20].

Dengue disease cases were most common in Chitwan and Jhapa districts, a region representing the commercial center of central-southern Nepal. As well, the Chitwan/Jhapa region is a transportation gateway to India and a hub for people travelling, primarily for economic reasons, between Nepal and India. Our data suggest that this region was likely the center of the 2016 outbreak and that DENV and dengue disease likely spread outward from there to other urban areas in Nepal. The spread of dengue disease from the Chitwan/Jhapa region to other parts of Nepal has been attributed to in part to ineffective vector control and an overall lack of public health awareness and response, although it is likely that other circumstances, including environmental, social and virological factors, contributed as well.

The first report of dengue disease incidence in the highlands of Nepal was during the 2010 outbreak [17]. In 2016, 3.12% of the reported cases of dengue were from highland regions, with 0.4% from the city of Kathmandu. Kathmandu is by far the largest urban area of Nepal, with around 4 million inhabitants as of 2016 [21]. Nepal is a poor country and Kathmandu especially has a high level of poverty featuring a considerable amount of sub-standard housing and water hygiene. The resource-poor health, social and economic infrastructures of Nepal in general and Kathmandu in particular, along with an increasing average temperature, are likely among the factors leading to the increased spread and incidence of DENV and dengue disease into highland areas. Although the 2006 dengue outbreak consisted of a relatively low number of reported cases of disease, all four DENV serotypes were detected [10]. However, the 2010 and 2013 dengue epidemics each featured a single dominate serotype, DENV-1 and DENV-2, respectively [18]. The occurrence over the past 12 years of multiple circulating serotypes, along with an overall increasing burden of dengue disease cases, suggests that the number of severe dengue disease cases is likely to rise in Nepal in the coming years [18]. Similar epidemiologic trends, in which ADE associated with multiple circulating serotypes has been considered a significant factor, have been observed in other regions such as in Indonesia and Brazil [22, 23]. Circulation of DENV-1 was also documented during 2014–2016 in several countries neighboring Nepal including India, China, Pakistan, Bangladesh and Sri Lanka [2428].

Conclusion

This report offers a clinical and epidemiological profile of the most recent major dengue outbreak in Nepal. Our documentation of the geographic incidence, symptomology and serotype association of the 2016 dengue outbreak will hopefully be useful to Nepalese government agencies to help strengthen mosquito surveillance and control as well as DENV vaccination, disease diagnosis and treatment programs.

Limitation

Authors could not performed sequencing of the isolated dengue virus because of limited budget.

Notes

Abbreviations

DF: 

dengue fever

DHF: 

dengue hemorrhagic fever

DSS: 

dengue shock syndrome

DENV-1: 

dengue virus serotype-1

DENV-2: 

dengue virus serotype-2

DENV-3: 

dengue virus serotype-3

DOHs: 

Department of Health Services

EDCD: 

Epidemiology and Disease Control Division

ELISA: 

Enzyme Linked immunosorbent Assay

NPHL: 

Nepal Public Health Laboratory

PCR: 

polymerase chain reaction

RDT: 

rapid diagnostic kit

TU: 

Tribhuvan University

Declarations

Authors’ contributions

RPK, SKC, BPU, UPG designed the study enrolled patients, performed the lab work, DAS, RR, BPG analyzed and interpreted the data and drafted the manuscript. All authors ensure for the publication. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank all the staff members of the various clinics and hospitals for their cooperation, efforts and expertise.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Corresponding author will be responsible for data-sharing.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Written consent was taken from participants and study was approved by Nepal Health Research Council [IRB Approval # 3I6/2017].

Funding

None.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
MB Kedia Dental College Private Limited, Birgunj, Tribhuvan University, Kathmandu, Nepal
(2)
Department of Biomedical Sciences, Oregon State University, Corvallis, USA
(3)
Virology Unit, Central Department of Biotechnology, Tribhuvan University, Kathmandu, Nepal
(4)
National Public Health Laboratory, Ministry of Health, Government of Nepal, Kathmandu, Nepal
(5)
Central Diagnostic Laboratory and Research Centre Pvt. Ltd, Kathmandu, Nepal

References

  1. Gupta BP, Lamsal M, Chaulagain S, Rauniyar R, Malla R, Shrestha S, Kurmi R, Manandhar KD. Emergence of dengue in Nepal. Virus Dis. 2018;29:1–5.View ArticleGoogle Scholar
  2. Rodenhuis-Zybert IA, Wilschut J, Smit JM. Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol Life Sci. 2010;67(16):2773–86.View ArticlePubMedGoogle Scholar
  3. Guzman MG, Harris E. Dengue. Lancet. 2015;385(9966):453–65.View ArticlePubMedGoogle Scholar
  4. Tsai C-Y, Lee K, Lee C-H, Yang KD, Liu J-W. Comparisons of dengue illness classified based on the 1997 and 2009 World Health Organization dengue classification schemes. J Microbiol Immunol Infect. 2013;46(4):271–81.View ArticlePubMedGoogle Scholar
  5. Organization WH. Dengue guidelines for diagnosis, treatment, prevention and control. new ed. Geneva: World Health Organisation; 2009.Google Scholar
  6. Lee K, Hsieh CJ, Lee CT, Liu JW. Diabetic patients suffering dengue are at risk for development of dengue shock syndrome/severe dengue: emphasizing the impacts of co-existing comorbidity (ies) and glycemic control on dengue severity. J Microbiol Immunol Infect. 2018. https://doi.org/10.1016/j.jmii.2017.12.005.Google Scholar
  7. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421–67.View ArticlePubMedGoogle Scholar
  8. Pol S, Rajderkar S, Bansode-Gokhe S. Where and how the dengue vector control program should focus its attention?—A study from Metropolitan City of Maharashtra. Int J Mosq Res. 2017;4(4):107–11.Google Scholar
  9. Wang XJ, Jiang SC, Wei HX, Deng SQ, He C, Peng HJ. The differential expression and possible function of long noncoding RNAs in liver cells infected by dengue virus. Am J Trop Med Hyg. 2017;97(6):1904–12.View ArticlePubMedGoogle Scholar
  10. Malla S, Thakur GD, Shrestha SK, Banjeree MK, Thapa LB, Gongal G, Ghimire P, Upadhyay BP, Gautam P, Khanal S. Identification of all dengue serotypes in Nepal. Emerg Infect Dis. 2008;14(10):1669.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Pandey BD, Morita K, Santa Raj Khanal TT, Miyazaki I, Ogawa T, Inoue S, Kurane I. Dengue virus, Nepal. Emerg Infect Dis. 2008;14(3):514.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Singh S, Gupta BP, Manakkadan A, Manandhar KD, Sreekumar E. Phylogenetic study reveals co-circulation of Asian II and Cosmopolitan genotypes of dengue virus serotype 2 in Nepal during 2013. Infect Genet Evol. 2015;34:402–9.View ArticlePubMedGoogle Scholar
  13. Hadinegoro SRS. The revised WHO dengue case classification: does the system need to be modified? Paediatr Int Child Health. 2012;32(sup1):33–8.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Anoop M, Issac A, Mathew T, Philip S, Kareem NA, Unnikrishnan R, Sreekumar E. Genetic characterization of dengue virus serotypes causing concurrent infection in an outbreak in Ernakulam, Kerala, South India. Indian J Exp Biol. 2010;48:849–57.PubMedGoogle Scholar
  15. Anoop M, Mathew AJ, Jayakumar B, Issac A, Nair S, Abraham R, Anupriya M, Sreekumar E. Complete genome sequencing and evolutionary analysis of dengue virus serotype 1 isolates from an outbreak in Kerala, South India. Virus genes. 2012;45(1):1–13.View ArticlePubMedGoogle Scholar
  16. Lanciotti RS, Calisher CH, Gubler DJ, Chang G-J, Vorndam AV. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol. 1992;30(3):545–51.PubMedPubMed CentralGoogle Scholar
  17. Subedi D, Taylor-Robinson AW. Epidemiology of dengue in Nepal: history of incidence, current prevalence and strategies for future control. J Vector Borne Dis. 2016;53(1):1.PubMedGoogle Scholar
  18. Gupta BP, Tuladhar R, Kurmi R, Manandhar KD. Dengue periodic outbreaks and epidemiological trends in Nepal. Ann Clin Microbiol Antimicrob. 2018;17(1):6.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Thapa S, Pant ND, Shrestha R, Ganga G, Shrestha B, Pandey BD, Gautam I. Prevalence of dengue and diversity of cultivable bacteria in vector Aedes aegypti (L.) from two dengue endemic districts, Kanchanpur and Parsa of Nepal. J Health Popul Nutr. 2017;36(1):5.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Regmi L, Pandey K, Malla M, Khanal S, Pandey BD. Sero-epidemiology study of leptospirosis in febrile patients from Terai region of Nepal. BMC Infect Dis. 2017;17(1):628.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Lutz W, Butz WP. Samir Ke: World population and human capital in the twenty-first century: an overview. Oxford: Oxford University Press; 2017.Google Scholar
  22. Yamanaka A, Mulyatno KC, Susilowati H, Hendrianto E, Ginting AP, Sary DD, Rantam FA, Soegijanto S, Konishi E. Displacement of the predominant dengue virus from type 2 to type 1 with a subsequent genotype shift from IV to I in Surabaya, Indonesia 2008–2010. PLoS ONE. 2011;6(11):e27322.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Figueiredo LB, Cecílio AB, Ferreira GP, Drumond BP, De Oliveira JG, Bonjardim CA, Ferreira PCP, Kroon EG. Dengue virus 3 genotype 1 associated with dengue fever and dengue hemorrhagic fever, Brazil. Emerg Infect Dis. 2008;14(2):314.View ArticlePubMed CentralGoogle Scholar
  24. Tazeen A, Afreen N, Abdullah M, Deeba F, Haider S, Kazim S, Ali S, Naqvi I, Broor S, Ahmed A. Occurrence of co-infection with dengue viruses during 2014 in New Delhi, India. Epidemiol Infect. 2017;145(1):67–77.View ArticlePubMedGoogle Scholar
  25. Bodinayake CK, Tillekeratne LG, Nagahawatte A, Devasiri V, Arachichi WK, Strouse JJ, Sessions OM, Kurukulasooriya R, Uehara A, Howe S. Emergence of epidemic dengue-1 virus in the southern province of Sri Lanka. PLoS Negl Trop Dis. 2016;10(10):e0004995.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Lin YP, Luo Y, Chen Y, Lamers MM, Zhou Q, Yang XH, Sanyal S, Mok CKP, Liu ZM. Clinical and epidemiological features of the 2014 large-scale dengue outbreak in Guangzhou city, China. BMC Infect Dis. 2016;16(1):102.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Changal KH, Raina A, Raina M, Bashir R, Latief M, Mir T, Changal QH. Differentiating secondary from primary dengue using IgG to IgM ratio in early dengue: an observational hospital based clinico-serological study from North India. BMC Infect Dis. 2016;16(1):715.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Maude RR, Ghose A, Samad R, de Jong HK, Fukushima M, Wijedoru L, Hassan MU, Hossain MA, Karim MR, Sayeed AA. A prospective study of the importance of enteric fever as a cause of non-malarial febrile illness in patients admitted to Chittagong Medical College Hospital, Bangladesh. BMC Infect Dis. 2016;16(1):567.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement